Myelofibrosis Clinical Trials in Cleveland, Ohio

5 studies are recruiting for myelofibrosis in Cleveland, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

   This phase 1b/2a open-label study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of DISC-0974 as well as categorize the effects on hematologic response in participants with myelofibrosis or myelodysplastic syndrome and anemia.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Cleveland Clinic, Cleveland, Ohio

   Locations

   32 in total

   Run by

   Disc Medicine, Inc

   See if you can join NCT05320198 on ClinicalTrials.gov

2. A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

   The main aim of this study is to find out how well elritercept works to improve anemia in participants with myelofibrosis (MF) who are taking ruxolitinib when compared to placebo. Other aims are to learn how elritercept improves anemia compared to placebo; to learn if elritercept reduces tiredness,…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Cleveland Clinic, Cleveland, Ohio

   Locations

   195 in total

   Run by

   Takeda

   See if you can join NCT07623161 on ClinicalTrials.gov

3. A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

   The researchers are doing this study to find out whether the combination of ruxolitinib and ulixertinib is a safe and effective treatment for people with myelofibrosis. The researchers will test different doses of ulixertinib to find the highest dose that causes few or mild side effects in particip…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Cleveland Clinic, Cleveland, Ohio

   Locations

   9 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06773195 on ClinicalTrials.gov

4. A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

   The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assesse…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Cleveland Clinic, Cleveland, Ohio

   Locations

   70 in total

   Run by

   Karyopharm Therapeutics Inc

   See if you can join NCT05980806 on ClinicalTrials.gov

5. Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

   This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone. Subjects will start by receiving ruxolitinib alone in t…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Cleveland Clinic Cancer Center at Fairview Hospital, Cleveland, Ohio

   Locations

   215 in total

   Run by

   Kartos Therapeutics, Inc.

   See if you can join NCT06479135 on ClinicalTrials.gov